- Previous Close
6.12 - Open
8.24 - Bid 7.35 x --
- Ask 7.75 x --
- Day's Range
7.66 - 8.24 - 52 Week Range
6.12 - 33.59 - Volume
50 - Avg. Volume
219 - Market Cap (intraday)
1.21B - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-1.38 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
www.10xgenomics.com1,306
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 1KJ.F
View MorePerformance Overview: 1KJ.F
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1KJ.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1KJ.F
View MoreValuation Measures
Market Cap
965.75M
Enterprise Value
682.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.32
Price/Book (mrq)
1.16
Enterprise Value/Revenue
1.23
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-29.90%
Return on Assets (ttm)
-12.77%
Return on Equity (ttm)
-25.17%
Revenue (ttm)
610.79M
Net Income Avi to Common (ttm)
-182.63M
Diluted EPS (ttm)
-1.38
Balance Sheet and Cash Flow
Total Cash (mrq)
393.4M
Total Debt/Equity (mrq)
11.63%
Levered Free Cash Flow (ttm)
59.82M